DK1501826T3 - Substituerede indoler som alpha-1-agonister - Google Patents

Substituerede indoler som alpha-1-agonister

Info

Publication number
DK1501826T3
DK1501826T3 DK03714714T DK03714714T DK1501826T3 DK 1501826 T3 DK1501826 T3 DK 1501826T3 DK 03714714 T DK03714714 T DK 03714714T DK 03714714 T DK03714714 T DK 03714714T DK 1501826 T3 DK1501826 T3 DK 1501826T3
Authority
DK
Denmark
Prior art keywords
agonists
alpha
substituted indoles
indoles
substituted
Prior art date
Application number
DK03714714T
Other languages
Danish (da)
English (en)
Inventor
Saul Jaime-Figueroa
Lubica Raptova
Robert Greenhouse
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Application granted granted Critical
Publication of DK1501826T3 publication Critical patent/DK1501826T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Gynecology & Obstetrics (AREA)
  • Obesity (AREA)
  • Reproductive Health (AREA)
  • Child & Adolescent Psychology (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Nutrition Science (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
DK03714714T 2002-02-01 2003-01-23 Substituerede indoler som alpha-1-agonister DK1501826T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US35350802P 2002-02-01 2002-02-01
US41849202P 2002-10-15 2002-10-15
PCT/EP2003/000644 WO2003064387A2 (en) 2002-02-01 2003-01-23 Substituted indoles as alpha-1 agonists

Publications (1)

Publication Number Publication Date
DK1501826T3 true DK1501826T3 (da) 2007-01-29

Family

ID=27669110

Family Applications (1)

Application Number Title Priority Date Filing Date
DK03714714T DK1501826T3 (da) 2002-02-01 2003-01-23 Substituerede indoler som alpha-1-agonister

Country Status (18)

Country Link
US (1) US6852726B2 (zh)
EP (1) EP1501826B1 (zh)
JP (1) JP4209332B2 (zh)
KR (1) KR100656037B1 (zh)
CN (1) CN100378095C (zh)
AR (1) AR038341A1 (zh)
AT (1) ATE340792T1 (zh)
AU (1) AU2003218962B2 (zh)
BR (1) BR0307406A (zh)
CA (1) CA2473803A1 (zh)
DE (1) DE60308670T2 (zh)
DK (1) DK1501826T3 (zh)
ES (1) ES2271551T3 (zh)
MX (1) MXPA04007414A (zh)
PL (1) PL373410A1 (zh)
PT (1) PT1501826E (zh)
RU (1) RU2337909C2 (zh)
WO (1) WO2003064387A2 (zh)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0201635D0 (sv) 2002-05-30 2002-05-30 Astrazeneca Ab Novel compounds
TW200307542A (en) 2002-05-30 2003-12-16 Astrazeneca Ab Novel compounds
SE0202241D0 (sv) 2002-07-17 2002-07-17 Astrazeneca Ab Novel Compounds
UA79504C2 (en) * 2002-11-07 2007-06-25 Organon Nv Indols for treating diseases associated with androgen receptors
KR20050072812A (ko) 2002-11-07 2005-07-12 악조 노벨 엔.브이. 안드로겐-수용체와 관련된 질병의 치료에 효과적인 인돌
SE0301010D0 (sv) 2003-04-07 2003-04-07 Astrazeneca Ab Novel compounds
KR100751163B1 (ko) * 2003-05-09 2007-08-22 에프. 호프만-라 로슈 아게 알파-1 아드레날린 작용물질로서의 메틸 인돌 및 메틸피롤로피리딘
SE0301569D0 (sv) 2003-05-27 2003-05-27 Astrazeneca Ab Novel compounds
SE0302232D0 (sv) 2003-08-18 2003-08-18 Astrazeneca Ab Novel Compounds
SA04250253B1 (ar) 2003-08-21 2009-11-10 استرازينيكا ايه بي احماض فينوكسي اسيتيك مستبدلة باعتبارها مركبات صيدلانية لعلاج الامراض التنفسية مثل الربو ومرض الانسداد الرئوي المزمن
AU2004283139A1 (en) * 2003-10-14 2005-05-06 Oxagen Limited Compounds having CRTH2 antagonist activity
JP4448730B2 (ja) 2004-04-20 2010-04-14 富士フイルム株式会社 感光性組成物、該感光性組成物に用いられる化合物及び該感光性組成物を用いたパターン形成方法
TW200602317A (en) * 2004-04-23 2006-01-16 Akzo Nobel Nv Novel androgens
GB0415320D0 (en) 2004-07-08 2004-08-11 Astrazeneca Ab Novel compounds
GB0418830D0 (en) 2004-08-24 2004-09-22 Astrazeneca Ab Novel compounds
JP5208510B2 (ja) 2004-11-23 2013-06-12 アストラゼネカ・アクチエボラーグ 呼吸器疾患の処置に有用なフェノキシ酢酸誘導体
JP2008521829A (ja) 2004-11-30 2008-06-26 プレキシコン，インコーポレーテッド Ｐｐａｒ活性化合物
WO2006060535A2 (en) * 2004-11-30 2006-06-08 Plexxikon, Inc. Indole derivatives for use as ppar active compounds
GB0500604D0 (en) 2005-01-13 2005-02-16 Astrazeneca Ab Novel process
KR20140002082A (ko) * 2005-01-14 2014-01-07 유리젠, 인코포레이티드 하부 요로 장애 치료용 키트 및 개선된 조성물
JP5619356B2 (ja) * 2005-08-22 2014-11-05 シエル・インターナシヨネイル・リサーチ・マーチヤツピイ・ベー・ウイＳｈｅｌｌ Ｉｎｔｅｒｎａｔｉｏｎａｌｅ Ｒｅｓｅａｒｃｈ Ｍａａｔｓｃｈａｐｐｉｊ Ｂｅｓｌｏｔｅｎｖｅｎｎｏｏｔｓｈａｐ ディーゼル燃料及びディーゼルエンジンの操作法
TW200745003A (en) 2005-10-06 2007-12-16 Astrazeneca Ab Novel compounds
US8148572B2 (en) 2005-10-06 2012-04-03 Astrazeneca Ab Compounds
BRPI0707873A2 (pt) * 2006-02-15 2011-05-10 Allergan Inc compostos amida, Éster, tioamida e tiol Éster do Ácido indol-3-carboxÍlico carregando grupos arila ou heteroarila tendo atividade biolàgica antagonista de recptor de esfingosina-1-fosfato (s1p)
CN101460458A (zh) * 2006-02-15 2009-06-17 阿勒根公司 具有1－磷酸－鞘氨醇(s1p)受体拮抗剂生物活性的带芳基或者杂芳基基团的吲哚－3－羧酸的酰胺、酯、硫代酰胺和硫羟酸酯化合物
EP2125722A2 (en) 2006-05-26 2009-12-02 AstraZeneca AB Bi-aryl or aryl-heteroaryl substituted indoles
PE20090159A1 (es) 2007-03-08 2009-02-21 Plexxikon Inc COMPUESTOS DERIVADOS DE ACIDO INDOL-PROPIONICO COMO MODULADORES PPARs
UA100983C2 (ru) 2007-07-05 2013-02-25 Астразенека Аб Бифенилоксипропановая кислота как модулятор crth2 и интермедиаты
AU2009243730B2 (en) * 2008-05-05 2013-07-18 Polypeptide Laboratories Holding (Ppl) Ab Indolesulfonyl protecting groups for protection of guanidino and amino groups
EP2246326A1 (de) * 2009-05-02 2010-11-03 Bayer CropScience AG Verfahren zur Herstellung von Oxindolen und ortho-substituierten Anilinen und ihre Verwendung als Zwischenprodukte für Synthesen
EP2566481A4 (en) * 2010-05-06 2014-01-22 Merck Sharp & Dohme AS FAAH MODULATORS SUITABLE AZA-INDOL DERIVATIVES
TWI695831B (zh) * 2014-09-13 2020-06-11 香港商南北兄弟藥業投資有限公司 Ｃｒｔｈ２拮抗劑化合物及其用途
CN106674081A (zh) * 2016-12-18 2017-05-17 南京理工大学 一种3‑甲硫基吲哚衍生物合成方法
US20220153735A1 (en) * 2019-03-04 2022-05-19 Beth Israel Deaconess Medical Center, Inc. Orai Channel Inhibitors
WO2022166638A1 (zh) * 2021-02-02 2022-08-11 广东东阳光药业有限公司 吲哚衍生物的盐及其用途
WO2023183394A1 (en) * 2022-03-24 2023-09-28 Curasen Therapeutics, Inc. Alpha 1a-adrenergic receptor agonists and methods of use

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3404156A (en) 1966-02-23 1968-10-01 Sterling Drug Inc Imidazolin-2-yl-alkyl-substituted indoles
US3689655A (en) 1970-12-07 1972-09-05 Sterling Drug Inc Rodenticidal and rodent repellent compositions
US4654360A (en) 1984-06-01 1987-03-31 Syntex (U.S.A.) Inc. 1,2,3-trisubstituted indoles for treatment of inflammation
US5095031A (en) 1990-08-20 1992-03-10 Abbott Laboratories Indole derivatives which inhibit leukotriene biosynthesis
US5334597A (en) 1991-10-17 1994-08-02 Merck Frosst Canada, Inc. Indole carbamates as leukotriene antagonists
ZA939516B (en) 1992-12-22 1994-06-06 Smithkline Beecham Corp Endothelin receptor antagonists
US6175013B1 (en) 1994-06-10 2001-01-16 Eli Lilly And Company Imidazolinyl tachykinin receptor antagonists
DE19514579A1 (de) * 1995-04-20 1996-10-24 Boehringer Ingelheim Kg Verwendung von alpha¶1¶¶L¶-Agonisten zur Behandlung der Harninkontinenz
FR2735774B1 (fr) 1995-06-21 1997-09-12 Sanofi Sa Utilisation de composes agonistes du recepteur cb2 humain pour la preparation de medicaments immunomodulateurs, nouveaux composes agonistes du recepteur cb2 et les compositions pharmaceutiques les contenant
MX9703186A (es) 1995-09-01 1997-07-31 Lilly Co Eli Antagonistas del receptor del neuropeptido y de indolilo.
SG72827A1 (en) 1997-06-23 2000-05-23 Hoffmann La Roche Phenyl-and aminophenyl-alkylsulfonamide and urea derivatives
AU2201699A (en) 1997-12-19 1999-07-12 Eli Lilly And Company Hypoglycemic imidazoline compounds
GB9910110D0 (en) * 1999-04-30 1999-06-30 Glaxo Group Ltd Chemical compounds
US6323231B1 (en) 2000-02-17 2001-11-27 Abbott Laboratories Use of α1A adrenoceptor agonists with α1B and α1D antagonism for the treatment of stress urinary incontinence

Also Published As

Publication number Publication date
ES2271551T3 (es) 2007-04-16
WO2003064387A2 (en) 2003-08-07
AU2003218962B2 (en) 2008-09-25
EP1501826B1 (en) 2006-09-27
US6852726B2 (en) 2005-02-08
WO2003064387A3 (en) 2004-12-02
US20030220319A1 (en) 2003-11-27
KR100656037B1 (ko) 2006-12-11
DE60308670D1 (de) 2006-11-09
PL373410A1 (en) 2005-08-22
CA2473803A1 (en) 2003-08-07
JP2005522427A (ja) 2005-07-28
AR038341A1 (es) 2005-01-12
RU2004126613A (ru) 2005-07-10
CN1628113A (zh) 2005-06-15
RU2337909C2 (ru) 2008-11-10
KR20040077927A (ko) 2004-09-07
CN100378095C (zh) 2008-04-02
BR0307406A (pt) 2004-12-28
ATE340792T1 (de) 2006-10-15
PT1501826E (pt) 2007-01-31
JP4209332B2 (ja) 2009-01-14
DE60308670T2 (de) 2007-08-16
EP1501826A2 (en) 2005-02-02
MXPA04007414A (es) 2004-10-11

Similar Documents

Publication Publication Date Title
DK1501826T3 (da) Substituerede indoler som alpha-1-agonister
NO20044654L (no) Piperidinoylpiperidiner som 5-HTIF-agonister
IS7607A (is) Ný útskipt indól
DK1492785T3 (da) 2-hydroxy-3-heteroarylindol-derivater som GSK3-inhibitorer
NO20052887D0 (no) Pyridazinonderivater som GSK-3Beta inhibitorer.
NO20055680D0 (no) Heksahydropyridoisokinoliner som DPP-IV-inhibitorer
NO20051042L (no) Pyrimidylsulfonamidderivater som kemokinreseptormodulatorer
ATE392206T1 (de) Indolderivate als beta-2 agonisten
ATE478870T1 (de) Spiroindolinpiperidinderivate
DK1556385T3 (da) Heterocyclocarboxamid-derivater
DE60330372D1 (de) Indol-3-schwefelderivate
ATE438644T1 (de) Chinazolinderivate
DK1474408T3 (da) N-Phenyl-2-pyrimidinaminderivater
SE0500163L (sv) Sammansättning
DK1438289T3 (da) Indolderivater som cox II-inhibitorer
NO20051500D0 (no) Substituerte heterocyklylpyrimidiner.
DE60307512D1 (de) 3h-chinazoline -4-on derivaten
DK1556377T3 (da) Cyclopropylthienylcarboxamider som fungicider
ATE423771T1 (de) Tetrahydrochinolinderivate
ATE457299T1 (de) 4-hydroxymethyl-1-aryl-cyclohexylamin-derivativ
DE60324018D1 (de) Agonisten
DE50306277D1 (de) 4-alkyl-/4-alkenyl-/4-alkinylmethyl/-1-arylcyclohexylamin-derivate
NO20043610L (no) Fenylpyrimidinaminer som IgE inhibitorer
NO20044140D0 (no) New Composition
DK1487802T3 (da) 2,3-diaryl-pyrazolidin-derivater som neurotensin-nedbrydende enzyminhibitorer